丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

丹参注射液与异甘草酸镁抗肝纤维化的临床对比研究

Objective To observe the change of liver function and liver fibrosis indexes of the chronic hepatitis B patients that were treated by Danshen injection(DI) and magnesium isnglyeyrrhizinate(MI). Methods 80 chronic hepati-tis B patients based on the conventional treatment were randomly divided into D1 group(40 patients) and MI group(40 pa-tients). The two groups were used with DI and MI injection for 30 days respaetively and then,the levels of liver function and serum hepatic fibrosis(HA, LN, Ⅳ -C) were detected and compared before and after treatment. Results Treatment by DI and MI could both improve liver function significantly, the effect of Ml group was better than DI group(P < 0.05). Moreover, in improving serum hepatic fibrosis, the effect of DI group was better than MI group (P < 0.05). Conclusions The efficacy of the improvement to hepatic fibrosis DI is better than MI, while in improvement of liver function MI is superior to DI.     

低蛋白饮食对3/4期慢性肾脏病患者肾功能及营养状况的影响

Objective To assess the influences of low-protein diet on the renal function and nutritional status in patients with stage 3/4 chronic kidney diseases (CKD).Methods Totally 34 patients with stage 3/4 CKD were randomly divided into group A (protein intake:0.6 g·kg~(-1)·d~(-1);n=14) and B (protein intake:0.8 g·kg~(-1)·d~(-1);n=20).Anthropometric measurement and blood biochemical tests were performed,nutri-tional status was assessed,and 24-hour dietary recall survey was conducted before and after the treatment.Patients were followed up for 6 months.Results In group A,the creatinine level significantly decreased (P=0.010),while albumin level (P=0.042) and the intake of energy (P=0.018) and carbohydrate (P<0.001) signifi-cantly increased after the treatment In all the 34 patients,in group A and group B,the malnutrition rates were de-creased by 14.7%,7.2%,and 21.1% after nutritional intervention.Conclusion The low-protein diet (protein intake 0.6 g·kg~(-1)·d~(-1)),in which part of the staple food was replaced by wheat starch,can increase the in-takes of carbohydrate and energy and improve renal function and nutritional status in patients with stage 3/4 CKD.     

左旋卡尼汀与促红素联合应用对透析患者贫血和营养状况的影响

目的观察左旋卡尼汀联用促红素治疗透析患者贫血及对其营养状态改善的临床疗效。方法回顾性分析某院自2008年1月～2010年10月收治的维持血液透析的贫血患者52例,随机分为二组,观察组27例给予左旋卡尼汀联用促红素,对照组25例单独给用促红素,观察二组患者治疗前后血红蛋白(Hb)、血细胞比容(Hct)的变化,治疗后4、8、12周的血清白蛋白(Alb)、前白蛋白(PA)、血清转铁蛋白(TF)、相对体重(KBW)。结果左旋卡尼汀联用促红素组及促红素组针对Hb、Hct值与治疗前比较,差异均有统计学意义,P﹤0.05,P﹤0.01。治疗后左旋卡尼汀联用促红素组Hb、Hct与促红组比较,差异均有统计学意义,P﹤0.05。观察组与对照组治疗8周及12周,与治疗前比较,Alb、PA、TF、KBW均有显著升高,P﹤0.05,P﹤0.01。观察组升高水平高于对照组,P﹤0.05。结论左旋卡尼汀与促红素联用可改善透析患者贫血状态,提高营养水平。     

血液透析联合腹膜透析对尿毒症患者心功能及营养状态的影响

目的 探讨血液透析联合腹膜透析对尿毒症患者心功能及营养状态的影响.方法 98例尿毒症患者随机分为两组各49例,对照组采用腹膜透析治疗,观察组采用血液透析联合腹膜透析治疗,比较两组治疗前后的心功能、营养状态以及并发症.结果 治疗后,两组的LVEF、Hb含量、A1b含量均较治疗前显著升高,且观察组的各项指标均显著高于对照组...     

肾衰宁联合血液透析治疗慢性肾衰竭效果分析

目的对慢性肾衰竭患者实施肾衰宁联合血液透析治疗,观察治疗效果。方法选择本院2020年3月-2020年6月期间收治的60例肾衰竭患者,根据治疗性质随机分组,两组患者均采取血液透析治疗,其中30例单纯维持血液透析(对照组),30例采取血液透析+肾衰宁胶囊(研究组)。对比两组治疗效果。结果研究组血生化指标改善效果较对照组显著;研究组在联合治疗下有效率高于对照组;研究组并发症概率为(6.7%),低于对照组(26.7%)。结论对慢性肾衰竭患者实施肾衰宁联合血液透析治疗能够有效改善患者的血生化指标,同时能够提高治疗效果。     

血浆置换联合维持性血液透析治疗在重症尿毒症患者中的应用与护理

目的：探讨血浆置换（PE）联合维持性血液透析（MH）治疗和护理对重症尿毒症患者的影响。方法：选取2008年4月-2013年12月本院确诊治疗的重症尿毒症患者45例,依据随机数字表法分为维持性血液透析组（MH组）、维持性血液滤过组（MF组）和血浆置换联合维持性血液透析组（PEMH组）,每组15例患者。所有患者均给予常规护理、营养支持等综合治疗,MH组患者给予MH治疗,MF组患者给予MF治疗,PEMH组患者给予PEMH治疗及相应的护理,统计分析所有患者治疗前后血清中β2-微球蛋白（β2-MG）、总胆固醇（TC）水平和治疗后并发症发生情况以及生活质量。结果：治疗后,MH组血清中β2-MG、TC水平明均显高于MF组,MF组均明显高于PEMH组,差异均有统计学意义（P〈0.05）;治疗后,MH组总并发症发生率明显高于MF组,MF组均明显高于PEMH组,差异均有统计学意义（P〈0.05）;MH组躯体、认知、社会功能和健康状态评分明均显低于MF组,MF组均低于PEMH组,差异均有统计学意义（P〈0.05）。结论：PEMH治疗和护理可有效提高重症尿毒症患者酸碱、电解质的改善作用,有助于提高疗效,降低治疗后不良情况的发生,改善患者生活质量,值得临床作进一步推广。     

血液透析滤过串联血液灌流联合骨化三醇冲击治疗对血透患者继发性甲状旁腺功能亢进的临床疗效

目的探讨血液透析滤过串联血液灌流联合骨化三醇冲击治疗对维持性血液透析患者并发继发性甲状旁腺功能亢进的临床疗效。 方法选取2019年01月至2019年06月60例维持性血液透析并发继发性甲状旁腺功能亢进的患者作为研究对象，其中男性42例，女性18例；年龄20～68岁，平均(52±17.2)岁。对照组30例，每周常规血液透析3次，联合骨化三醇冲击治疗；研究组30例，每周常规血液透析1次，血液透析滤过1次，血液透析滤过＋血液灌流1次，联合骨化三醇冲击治疗。观察两组患者血钙、血磷、血甲状旁腺素、碱性磷酸酶(ALP)等各项指标变化，并对两组患者的临床症状进行比较分析。 结果两组患者血甲状旁腺素均降低(P<0.05)；研究组患者的血甲状旁腺素、血磷、碱性磷酸酶明显低于对照组(P<0.05)；对照组治疗后血钙水平上升，较治疗前差异有统计学意义(P<0.05)；研究组治疗前后血钙水平差异无统计学意义(P>0.05)。 结论对维持性血液透析继发甲状旁腺功能亢进患者应用血液透析滤过串联血液灌流联合骨化三醇冲击治疗不仅能有效降低血甲状旁腺素、血磷、碱性磷酸酶水平，不影响血钙水平，且更能改善患者临床症状，提高生活质量。     

慢性阻塞性肺疾病急性加重期并发呼吸衰竭病人肠内营养联合生长激素的疗效观察

目的:探讨早期肠内营养(EEN)联合重组人生长激素(rhGH)对慢性阻塞性肺疾病急性加重期(AECOPD)并发呼吸衰竭的疗效。方法:将90例AECOPD病人随机分为试验组和对照组,每组45例。对照组病人给予常规临床治疗,试验组病人在此基础上给予EN联合皮下注射GH,观察两组病人机械通气时间,检测两组病人治疗期间营养指标、免疫指标和T细胞亚群等。结果:试验组病人治疗后1周的血清清蛋白、转铁蛋白、前清蛋白、血红蛋白、纤维连接蛋白、免疫球蛋白和T细胞亚群均明显高于对照组(P<0.05),机械通气时间明显缩短(P<0.05),病死率减低(P<0.05)。结论:EN联合GH治疗不仅能缩短AECOPD并发呼吸衰竭病人机械通气时间,而且还能改善病人营养状况,增强免疫功能,提高临床疗效。     

综合性营养评估法在维持性血液透析患者中的应用

目的对血液透析患者的几项营养指标进行评估。方法对142例维持性血液透析（MHD）患者进行主观综合性营养评估（SGA）、膳食调查、生化参数的测定。结果依据SGA评分,在营养良好、轻中度营养不良及重度营养不良三组间进行以下指标比较：平均每日每公斤体重能量（DEI）和蛋白质摄入（DPI）、血白蛋白（ALb）,均有显著性差异（P〈0.001～0.05）。但营养良好组的DEI和DPI异常率高达46.0%、49.0%,重度营养不良组中各指标异常率均在80%以上。血前白蛋白（PA）与血ALb有显著相关（P〈0.01）,与DPI、DEI均无相关。结论SGA是评价MHD患者营养状况的简便方法,但还需其它反映营养状况不同侧面指标的补充,如DEI、DPI、血ALb、血PA。     

营养护理在提高终末期肾病血液透析患儿营养水平和生活质量中的作用

目的探讨终末期肾病血液透析患儿实施常规护理联合营养护理对营养水平与生活质量的影响。方法选取2016—2017年收治的90例终末期肾病患儿,采用随机数字表法分为对照组和实验组,每组45例。对照组患儿实施常规护理,实验组患儿在对照组基础上实施营养护理,比较2组患儿营养水平、生活质量及不良反应发生率。结果实验组营养正常率为66.67%,显著高于对照组的37.78%(P<0.05)。实验组患儿生理职能、情绪职能、心理职能、认知职能评分均高于对照组(P<0.05)。实验组、对照组患儿不良反应发生率分别为8.89%、26.67%,差异有统计学意义(P<0.05)。结论终末期肾病血液透析患儿实施常规护理联合营养护理的临床效果十分显著,能够有效提高患儿营养水平与生活质量,减少不良反应的发生。     

腹膜透析联合血液透析对慢性肾衰竭患者钙磷代谢及生化指标的影响

目的 探讨腹膜透析联合血液透析对慢性肾衰竭患者钙磷代谢及生化指标的影响.方法 选取2018年1月至2019年12月我院收治的64例慢性肾衰竭患者,根据治疗方法 不同分为对照组(n=31)和观察组(n=33).对照组采用血液透析治疗,观察组采用腹膜透析联合血液透析治疗.比较两组患者治疗前、治疗6个月后钙磷代谢及生化指标[...     

华法林联合氯吡格雷对冠心病合并房颤患者心功能指标及生活质量的影响

目的 探讨华法林联合氯吡格雷治疗冠心病合并房颤的效果,以及对患者生活质量和心功能指标的影响.方法 选取2018年12月—2019年12月沈阳二四五医院心血管内科收治的84例冠心病伴房颤患者,依据治疗方案的用不同分为对照组和观察组各42例.对照组采用冠心病和房颤常规方案联合氯吡格雷治疗,观察组在常规用药基础上联合应用华法...